期刊文献+

小干扰RNA抑制骨肉瘤细胞组织蛋白酶K表达及生长与侵袭的研究 被引量:1

Inhibitory effect of small interfering RNA on Cathepsin K expression and cell growth and invasion ability of osteosarcoma cells
原文传递
导出
摘要 目的 观察人小干扰RNA (siRNA)沉默入骨肉瘤细胞株MG63组织蛋白酶K(Cathepsin K)对增殖和侵袭影响.方法 利用脂质体将Cathepsin K siRNA转染MG63,通过反转录-聚合酶链反应(RT-PCR)与Western blot分别检测Cathepsin K mRNA及蛋白质表达,增殖与迁移实验评估沉默Cathepsin K后MG63增殖与侵袭改变.结果 siRNA能有效地抑制Cathepsin KmRNA及蛋白质表达(0.05±0.16、4.00±0.08),与对照组(1.10 ±0.06、1.00±0.21)比较,差异有统计学意义(P<0.01);沉默Cathepsin K细胞增殖(100.00±0.09)明显低于对照组(40.00±0.13,P<0.01);Cathepsin K siRNA组迁移细胞数[(45.0±4.9)个]明显低于对照组[(112.0±8.0)个,P<0.01].结论 siRNA可有效抑制Cathepsin K表达,降低MG63增殖与侵袭能力. Objective To explore the inhibitory effect of small interfering RNA (siRNA) on Cathepsin K expression and growth and invasion ability of osteosarcoma cells.Methods A Cathepsin K mRNA-targeting siRNA was transfected into MG63 cells with lipidosme.Reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting were used to detect the mRNA and protein expression of Cathepsin K respectively.Methyl thiazol tetrazolium (MTT) and Transwell assays were applied to measure the proliferation and invasion of osteosarcoma cells.Results The mRNA and protein expression levels of Cathepsin K in the cells transfected with Cathepsin K siRNA (0.05 ±0.16 and 4.00 ±0.08) were lower than in the control group (1.10 ±0.06 and 1.00 ±0.21,P 〈0.01).The proliferation index in Cathepsin K-silenced cells (100.00 ±0.09) was lower than that in control group (40.00 ±0.13,P 〈0.01).The number of invasion cells in Cathepsin K siRNA group (45.0 ±4.9) was significantly less han in control group (112.0 ± 8.0,P 〈 0.01).Conclusion siRNA can effectively silence the expression of Cathepsin K and inhibit the proliferation and invasion of osteosarcoma cells.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2015年第3期579-581,共3页 Chinese Journal of Experimental Surgery
关键词 骨肉瘤 组织蛋白酶K RNA干扰 增殖 侵袭 Osteosarcoma Cathepsin K Small interfering RNA Proliferation Invasion
  • 相关文献

参考文献17

  • 1Jiang L, He A, Zhang Q, et al. miR-126 inhibits cell growth,invasion, and migration of osteosarcoma cells by downregulating ADAM-9 [ J ]. Tumour Bio1,2014,35 ( 12 ) : 12645-12654.
  • 2Novinec M, Lenarcic B. Cathepsin K : a unique collagenolytic cysteine peptidase[ J]. Biol Chem,2013,394(9) :1163-1179.
  • 3Husmann K, Muff R, Bolander ME, et al. Cathepsins and osteosarco- ma:expression analysis identifies cathepsin K as an indicator of me- tastasis [ J ]. Mol Carcinog,2008,47 ( 1 ) :66-73.
  • 4蔡槱伯,孙宇庆.骨肉瘤诊断与治疗的进展[J].癌症进展,2005,3(4):308-315. 被引量:6
  • 5Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma:a- nalysis within a group of patients, all of whom developed lung metasta- sis[J]. Mod Pathol,2006,19(5):738-745.
  • 6Ferrari S, Zanella L, Alberghini M, et al. Prognostic significance of im- expression of Ezrin in non-metastatic high-grade osteosarcoma [ J ]. Pediatr Blood Cancer,2008,50 (4) :752-756.
  • 7Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins [ J ]. Biochem Soc Symp,2003, (70) :179-199.
  • 8Husmann K, Muff R, Bolander ME, et al. Cathepsins and osteosarco- ma : Expression analysis identifies cathepsin K as an indicator of me- tastasis [ J ]. Mol Carcinog,2008,47 ( 1 ) :66-73.
  • 9Kleer CG, Bloushtain-Qimron N, Chen YH, et al. Epithelial and stror- nal cathepsin K and CXCL14 expression in breast tumor progression [ J ]. Clin Cancer Res,2008,14 ( 17 ) :5357-5367.
  • 10Srivastava A, Fuchs B, Zhang KB, et al. High WTI expression is asso- ciated with very poor survival of patients with esteogenic sarcoma me- tastasis [ J ]. Clin Cancer Res ,2006,12 (14) :4237-4243.

二级参考文献25

  • 1陈雷,林建华,张声.基质金属蛋白酶-9和组织金属蛋白酶抑制剂-1在骨肉瘤中的表达及其意义[J].中华实验外科杂志,2004,21(12):1522-1523. 被引量:11
  • 2[1]Coventry MB and Dahlin DC. Osteogenic sarcoma: A critical analysis of 340 cases. J Bone Joint Surg Am, 1957, 39:741
  • 3[2]Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med, 1986, 314:1600
  • 4[3]Unni KK: Dahlin's Bone Tumors: General Aspects and Data on11, 087 Cases. Ed. 5th. Philadelphia, Lippincott-Raven,1996
  • 5[4]Boyko OB, Cory DA, Cohen MD, et al. MR imaging of osteogenic and Ewing's sarcoma. AJR Am J Roentgenol, 1987, 148:317
  • 6[5]Mankin HJ, Gebhardt MC, Jennings LC, et al. Long-term results of allograft replacement in the management of bone tumors.Clin Orthop, 1996, 324:86
  • 7[6]Muscolo DL, Ayerza MA, and Aponte-Tinao LA. Survivorship and radiographic analysis of knee osteoarticular allografts. Clin Orthop, 2000, 373: 73
  • 8[7]Malawer MM, and Chou LB. Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas. J Bone Joint Surg Am, 1995, 77:1154
  • 9[8]Manfrini M, Gasbarrni A, Malaguti C, et al. Intraepiphyseal resection of the proximal tibia and its impact on lower limb growth. Clin Orthop, 1999, 358: 111
  • 10[9]Eckardt JJ, Kabo JM, Kelley CM, et al. Expandable endoprosthesis reconstruction in skeletally immature patients with tumors. ClinOrthop, 2000, 373:51

共引文献11

同被引文献2

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部